Risedronate as a therapeutic trial post-hysterectomy in premenopausal women to prevent osteoporosis
Background: Osteoporosis is a skeletal defect manifested by a reduction of bone strength as a result of reduced bone mass to the extent that there is a higher risk of fracture even on minor trauma. Hysterectomy in a premenopausal woman is a well known cause of ovarian failure resulting in an increased risk of osteoporosis.
Objective : To clarify bisphosphonate's preventive effect on osteopenia and osteoporosis in premenopausal women after hysterectomy.
Type of the study: Cross –sectional study.
Method: 84 premenopausal females post hysterectomy aged between 40 – 50 years, were enrolled in this randomized controlled double blinded trail at Al Yarmouk teaching hospital and private clinic in Baghdad for a period of two years from Augest 2011 till July 2013. Participants were assigned as: 1stgroup (study group 42 women): received risedronate treatment "over a period of one year" with calcium and vitamin D; and 2ndgroup (control group 42 women) were taken as a matched group for:"age, body mass index (BMI) and fracture history", received only calcium and vitamin D as a placebo. Bone density had been assayed at the end of the year for all participants and evaluated for osteopenia and osteoporosis.
Results: Osteopenia and osteoporosis were significantly lower in the risedronate arm as compared to those not received the drug "14.3% & 11.9% versus 26.1% & 19% respectively".
Conclusion: The bone mineral density results were significantly better in those who received risedronate than those not received the drug.